A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).

Authors

Antonio Llombart-Cussac

Hospital Arnau Vilanova, Valencia, Spain

Antonio Llombart-Cussac , Meritxell Bellet , Pilar Zamora , Manuel Ruiz , Joseph Gligorov , Serena Di Cosimo , Peter Schmid , Shaheenah Dawood , Henri Roche , Frederic Marme , Elena Aguirre , Javier Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Breakthrough

bookmark_border

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.

First Author: Joohyuk Sohn

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

First Author: Tomás Pascual

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

First Author: Elgene Lim

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study.

First Author: Tamta Makharadze